Loading
Loading
Growth Hormone & Secretagogues · 10mg
Choose dose
Janoshik-tested · 10 vials per kit
Sermorelin is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH) studied in preclinical and clinical research for its GH-stimulating properties. Research has examined its potential to stimulate the anterior pituitary to secrete endogenous growth hormone via physiological feedback mechanisms. Studies have explored applications in growth hormone deficiency, aging-related GH decline, and body composition research.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Sermorelin
GHRH(1-29) — Geref
Sermorelin is the biologically active N-terminal 29-amino-acid fragment of endogenous GHRH(1-44). First synthesised in the 1970s and FDA-approved in 1997 as Geref for GH deficiency testing and paediatric GH deficiency treatment. Withdrawn from the US commercial market in 2008 due to manufacturing changes, it remains widely studied as a natural GHRH analog. Half-life is 10-20 minutes — shorter than Modified GRF 1-29 due to the absence of stabilising amino acid substitutions.
Sermorelin is structurally identical to the first 29 residues of endogenous GHRH and acts via the same GHRHr agonism on pituitary somatotrophs. It stimulates GH release in a manner that preserves hypothalamic-pituitary feedback regulation, maintaining the sensitivity of pituitary somatotrophs to negative feedback from IGF-1 and GH — in contrast to exogenous GH administration which bypasses this regulation and can suppress endogenous GH production.
Research areas include GH deficiency (paediatric and adult), anti-ageing protocols (restoring age-related decline in GH pulsatility), body composition, sleep quality (GH is preferentially secreted during delta sleep; Sermorelin may enhance this nocturnal pulse), bone density, and cardiovascular function. Its ability to stimulate GH through physiological pituitary pathways makes it distinct from exogenous GH in research applications.
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
